Cipla, Hetero roll out Aranesp biosim; Judge backs Novartis' Exelon patents;

@FiercePharma: Now out: This week's issue of FierceVaccines. Weekly report | Follow @FiercePharma

@TracyStaton: Trending now at FiercePharma: Novo Nordisk lays out plans to recruit 6,000 workers in R&D, production. Story | Follow @TracyStaton

@EricPFierce: How much are the big dogs of Big Pharma paid? A lot. See the top 15 highest paid CEOs here. | Follow @EricPFierce

@CarlyHFierce: Czech scientists have a Lyme disease vaccine ready for animal use. A few of my favorite things in here, and Lyme disease isn't one of them. Story | Follow @CarlyHFierce

> India's Cipla teamed up with Hetero to launch a biosimilar version of Amgen's ($AMGN) anemia treatment Aranesp in its home country. Release | Report

> A Delaware judge found that generics maker Watson Laboratories, now owned by Actavis ($ACT), stepped on Novartis' ($NVS) patents for the Alzheimer's treatment patch Exelon. Release | Report

> U.S.-based Mylan ($MYL) pulled batches of an injectable antibiotic, made in Poland for sale under the Agila brand, because of possible impurities. Report

> The U.K.'s cost-effectiveness agency will hold an oral appeal hearing for the prostate cancer treatment Firmagon, which was approved in April, but for a limited patient group. Release

> The Indian generics maker Dr. Reddy's pulled more than 13,000 bottles of its copy of AstraZeneca's ($AZN) blood pressure treatment Toprol XL. Report

Medical Device News

@FierceMedDev: EnteroMedics up in early trading after mixed FDA panel vote. More | Follow @FierceMedDev

@StacyALawrence: Medtronic merger could give Covidien execs an $80M payout. Story | Follow @StacyALawrence

@MichaelGFierce: UPenn team combats Parkinson's with immunotherapy that targets neuron killers. Story from FierceBiotechResearch | Follow @MichaelGFierce

@EmilyWFierce: Single gene mutations that lower triglyceride levels could spur the development of a new class of heart disease drugs. Article | Follow @EmilyWFierce

> Data: Medtronic personalized defibrillator safer, cheaper. More

> Covidien endovascular unit could be target for cuts after Medtronic merger. Story

> Covidien recalls potentially faulty Hydrofinity guidewire. Article

Biotech News

@FierceBiotech: Navitor grabs a $23.5M A round to tackle a key crossroad for disease. More | Follow @FierceBiotech

@JohnCFierce: Man, that Burrill lawsuit makes for interesting reading. Story | Follow @JohnCFierce

@DamianFierce: J&J Innovation's summer class of biotechs targets obesity, insomnia, heart failure, cancer and more. News | Follow @DamianFierce

> Zafgen, Ardelyx bank $156M in IPOs, recalling biotech's winter boom. More

> J&J pays $30M to grab rights to Vertex program. Item

> Takeda dumps its top cancer contender after a late-stage struggle. Story

Vaccines News

> Merck, Sanofi JV wins anal cancer indication for Gardasil in EU. Story

> Themis Chikungunya prophylactic hits Phase I goal. More

> Pfizer puts the heat on Novartis with FDA MenB filing. Article

> Novartis submits Bexsero to FDA in race for MenB market. News

> MenB survivors call for Bexsero coverage in Australia. Item

> Novartis facility grabs FDA license to produce cell-culture vaccines. Report

Pharma Manufacturing News

> EMA GMP inspectors working group making updates for this year. Item

> Ranbaxy's FDA problems stymie launch of generic Nexium and the relief it would bring to consumers. More

> Dr. Reddy's initiates 2 recalls even as it invests to remove human error. Story

> Grifols doubles capacity with new U.S. plasma fractionation plant. Article

> Counterfeit antibiotics feed drug resistance, superbugs. News

> FDA finds fault with Chinese API maker. Report

And Finally... Americans slept more last year, but worked less, thanks to a groggy economy. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.